Video Experimental Relacionado
Updated: Sep 22, 2025
09:15
Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
Published on: October 20, 2022
2.4K
ADAR1 enmascara la promesa inmunoterapéutica del cáncer de la necroptosis impulsada por ZBP1
Ting Zhang1, Chaoran Yin1, Aleksandr Fedorov2
1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Nature
|May 25, 2022
Resumen
La enzima de edición de ARN ADAR1 dificulta la inmunidad contra el cáncer al suprimir los ARNZ. La activación de ZBP1 con CBL0137 evita el ADAR1, restaurando la respuesta inmune en los cánceres resistentes.
Área de la Ciencia:
- Inmunología
- Biología molecular
- En el campo de la oncología
Sus antecedentes:
- La respuesta limitada del paciente al bloqueo del punto de control inmune (ICB, por sus siglas en inglés) destaca los mecanismos de resistencia.
- La enzima ADAR1 reprime los dsRNA inmunogénicos, lo que contribuye a la resistencia a las ICB.
- El papel de ADAR1 en la acumulación de Z-RNA y la activación de ZBP1 sigue siendo inexplorado.
Objetivo del estudio:
- Investigar el papel de ADAR1 en la regulación del ARN-Z y la activación de ZBP1.
- Identificar estrategias terapéuticas para superar la resistencia a las ICB mediadas por ADAR1.
- Evaluar CBL0137 como un activador de ZBP1 para mejorar la inmunidad antitumoral.
Principales métodos:
- Agotamiento y mutación de ADAR1 en modelos celulares y en ratones.
- Análisis de la acumulación de Z-ARN y la activación de ZBP1.
- Tratamiento con la pequeña molécula CBL0137 y evaluación de la necroptosis dependiente de ZBP1 y la respuesta a la ICB.
Principales resultados:
- El agotamiento/mutación de ADAR1 condujo a la acumulación de Z-ARN y a la activación de ZBP1, induciendo la necroptosis.
- La pequeña molécula CBL0137 activa el ZBP1 induciendo la formación de Z-ADN.
- El tratamiento con CBL0137 revirtió la falta de respuesta de ICB en modelos de ratón con melanoma.
Conclusiones:
- ADAR1 reprime activamente los ARNZ endógenos, enmascarando la necroptosis mediada por ZBP1 y la inmunogenicidad tumoral.
- La necroptosis mediada por ZBP1 es un nuevo determinante de la inmunidad antitumoral.
- La activación terapéutica de ZBP1 presenta una estrategia traducible para mejorar la eficacia de ICB en cánceres resistentes.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:31The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:53Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
01:17The Extrinsic Apoptotic Pathway
6.7K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.7K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.5K
01:30Apoptosis
12.0K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
12.0K